Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/22/2023 | $8.00 | Equal-Weight | Morgan Stanley |
| 3/16/2023 | $17.00 | Buy | Needham |
| 9/16/2022 | $20.00 | Overweight | KeyBanc Capital Markets |
| 4/18/2022 | $10.00 | Buy → Neutral | BofA Securities |
| 3/4/2022 | $32.00 → $10.00 | Outperform → Market Perform | SVB Leerink |
| 12/8/2021 | $30.00 → $32.00 | Outperform | SVB Leerink |
| 9/21/2021 | $37.00 | Buy | Berenberg |
| 8/16/2021 | $33.00 → $30.00 | Outperform | SVB Leerink |
Boltz-2 is the first biomolecular co-folding model to combine structure and binding affinity prediction, approaching the accuracy of physics-based free energy perturbation (FEP) calculations but at speeds up to 1000x faster in standard benchmarks The development of this open source model for academic and commercial use was a collaborative effort, combining MIT's deep academic expertise with Recursion's AI research and NVIDIA-accelerated supercomputer, BioHive-2 Salt Lake City, UT, June 06, 2025 (GLOBE NEWSWIRE) -- Researchers at the Massachusetts Institute of Technology (MIT) Computer Science and Artificial Intelligence Lab (CSAIL) and Jameel Clinic, alongside TechBio company
Equity Insider News Commentary Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, June 4, 2025 /PRNewswire/ -- Equity Insider News Commentary – Generative AI is transforming healthcare faster than almost any other sector, according to a new McKinsey report. In a March survey of senior leaders across payers, providers, and healthcare services groups, 85% said they're actively using or exploring the technology. McKinsey's Global Institute estimates Gen AI could unlock $60–110 billion in annual value across pharma and medical products alone. With more AI pilot programs running than ever before, the tech world is racing to meet demand — including new efforts from Avant Technologies, Inc.
Salt Lake City, May 30, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today its participation in the following upcoming investor conferences: Jefferies Global Healthcare Conference — Thursday, June 5, 2025 Goldman Sachs 46th Annual Global Healthcare Conference — Tuesday, June 10, 2025 TDCowen 4th Annual Tools/Dx Revolution Conference — Monday, June 23, 2025 Webcasts may be found in the events section of the Recursion Investor Relations website at ir.recursion.com. About RecursionRecursion (NASDAQ:RXRX) is a clinical stage TechBio company leading the space by decoding biology to
Salt Lake City, UT, April 28, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today it will provide business updates and report its first quarter 2025 financial results on Monday, May 5, 2025, before the open of the financial markets. Recursion will host a (L)earnings Call on May 5, 2025 at 8:00 am ET / 6:00 am MT / 1:00 pm GMT. The company will broadcast the live stream from Recursion's X (formerly Twitter), LinkedIn, and YouTube accounts. Investors, analysts, and the public will be able to ask questions of the company by submitting questions here: https://forms.gle/LYZwaVdPJidC7x259. Abo
Salt Lake City, UT, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, announced today it will provide business updates and report its fourth quarter and full year 2024 financial results on Friday, February 28, 2025, before the open of the financial markets. Recursion will host a (L)earnings Call on February 28, 2025 at 8:30 am ET / 6:30 am MT / 1:30 pm GMT. The company will broadcast the live stream from Recursion's X (formerly Twitter), LinkedIn, and YouTube accounts. Investors, analysts, and the public will be able to ask questions of the company by submitting questions here: https://bit
REC-617, a precision designed molecule, demonstrated dose-linear pharmacokinetics (PK) with rapid absorption and robust pharmacodynamic (PD) biomarker modulation, suggesting substantial target engagementConfirmed partial response (PR) observed during monotherapy dose-escalation in a patient with platinum-resistant ovarian cancer, treated with 4 lines of prior therapy in advanced setting, durable response ongoing after more than 6 months of treatmentAdditional 4 patients demonstrated a best response of stable disease (SD) for up to 6 months of treatmentPlans to continue monotherapy dose escalation and initiate combination studies in 1H 2025 SALT LAKE CITY, Dec. 09, 2024 (GLOBE NEWSWIRE) --
SC 13G/A - RECURSION PHARMACEUTICALS, INC. (0001601830) (Subject)
SC 13G/A - RECURSION PHARMACEUTICALS, INC. (0001601830) (Subject)
SC 13G/A - RECURSION PHARMACEUTICALS, INC. (0001601830) (Subject)